Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY5O1U)

• Drug Name: BENZOYLENUREA Drug Info
• Synonyms: Benzoyleneurea; 86-96-4; quinazoline-2,4(1H,3H)-dione; 2,4(1H,3H)-Quinazolinedione; 2,4-Dihydroxyquinazoline; Quinazolinedione; Benzouracil; Quinazoline-2,4-diol; Quinazoline-2,4-dione; 1H-Quinazoline-2,4-dione; Urea, benzoylene-; 1,2,3,4-Tetrahydroquinazoline-2,4-dione; 2-Keto-4-quinazolinone; 2,4-Dioxotetrahydroquinazoline; NSC 2108; (1H,3H)Quinazoline dione-2,4; (1H,3H)-Quinazoline-2,4-dione; EINECS 201-712-6; (1H,3H)Quinazoline dione-2,4 [French]; AI3-28016; CHEMBL421646; 1H,3H-quinazoline-2,4-dione; UNII-18K00A531C

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 64048
  CAS Number: CAS 86-96-4
  TTD Drug ID: DMY5O1U

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 3A (PDE3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[3]
Aminophylline	DML2NIB	Bronchial asthma	CA23	Approved	[4]
Anagrelide	DMSQ8MD	Thrombocythemia	3B63	Approved	[5]
Enoximone	DMQVZJD	Congestive heart failure	BD10	Approved	[6]
VESNARINONE	DMBKX3C	Cardiac failure	BD10-BD13	Approved	[7]
BEMORADAN	DMUL6GY	Heart failure	BD10-BD13	Phase 2	[8]
CI-930	DMADPQX	N. A.	N. A.	Discontinued in Phase 2	[9]
EMD-53998	DMVS8IE	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 1	[8]
IMAZODAN	DMWTFO3	N. A.	N. A.	Terminated	[10]
LAS-31180	DMW2K1L	Heart failure	BD10-BD13	Terminated	[11]

Drug(s) Affected By Potassium voltage-gated channel subfamily KQT member 3 (KCNQ3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[12]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[13]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[15]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[16]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[17]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[18]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[19]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[20]
Sulforaphane	DMQY3L0	Skin disease	EA00-EM0Z	Investigative	[21]

Drug(s) Affected By Potassium voltage-gated channel subfamily KQT member 2 (KCNQ2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[22]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[12]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[15]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[25]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[19]

Drug(s) Affected By Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[23]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[27]
Gentamicin	DMKINJO	Bacteremia	1A73	Approved	[26]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[26]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[26]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[15]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[28]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[29]

Drug(s) Affected By Potassium voltage-gated channel subfamily KQT member 5 (KCNQ5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[30]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[33]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[34]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[19]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[20]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[35]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 3A (PDE3A)	TT06AWU	PDE3A_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily KQT member 2 (KCNQ2)	OT3CXQJT	KCNQ2_HUMAN	Gene/Protein Processing	[2]
Potassium voltage-gated channel subfamily KQT member 3 (KCNQ3)	OTXVBEED	KCNQ3_HUMAN	Gene/Protein Processing	[2]
Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4)	OT29B58J	KCNQ4_HUMAN	Gene/Protein Processing	[2]
Potassium voltage-gated channel subfamily KQT member 5 (KCNQ5)	OTMED202	KCNQ5_HUMAN	Gene/Protein Processing	[2]

References

• [1] CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem. 2008 Jul;43(7):1349-59.
• [2] KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels. J Neurosci Methods. 2011 Aug 30;200(1):54-62. doi: 10.1016/j.jneumeth.2011.06.014. Epub 2011 Jun 23.
• [3] A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
• [4] Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
• [5] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
• [6] Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
• [7] Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [9] Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
• [10] 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
• [11] Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
• [12] The Sensorless Pore Module of Voltage-gated K+ Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine. J Biol Chem. 2016 Feb 5;291(6):2931-7. doi: 10.1074/jbc.M115.683185. Epub 2015 Dec 1.
• [13] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [14] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [15] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [16] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [17] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [18] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [19] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [20] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [21] Sulforaphane-induced apoptosis in human leukemia HL-60 cells through extrinsic and intrinsic signal pathways and altering associated genes expression assayed by cDNA microarray. Environ Toxicol. 2017 Jan;32(1):311-328.
• [22] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [23] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [24] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [25] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [26] Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
• [27] The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77.
• [28] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [29] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [30] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [31] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [32] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [33] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [34] BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16;146(6):904-17.
• [35] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.